Your browser doesn't support javascript.
loading
A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.
Conway, Anna; Valerio, Heather; Alavi, Maryam; Silk, David; Treloar, Carla; Hajarizadeh, Behzad; Marshall, Alison D; Martinello, Marianne; Milat, Andrew; Dunlop, Adrian; Murray, Carolyn; Prain, Bianca; Henderson, Charles; Amin, Janaki; Read, Phillip; Marks, Pip; Degenhardt, Louisa; Hayllar, Jeremy; Reid, David; Gorton, Carla; Lam, Thao; Christmass, Michael; Wade, Alexandra; Montebello, Mark; Dore, Gregory J; Grebely, Jason.
Affiliation
  • Conway A; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Valerio H; Centre for Social Research in Health, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Alavi M; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Silk D; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Treloar C; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Hajarizadeh B; Centre for Social Research in Health, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Marshall AD; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Martinello M; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Milat A; Centre for Social Research in Health, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Dunlop A; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Murray C; Centre for Epidemiology and Evidence, NSW Health, Sydney, NSW 2065, Australia.
  • Prain B; Hepatitis NSW, Surry Hills, NSW 2010, Australia.
  • Henderson C; Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW 2300, Australia.
  • Amin J; Population Health Strategy & Performance, NSW Health, Sydney, NSW 2065, Australia.
  • Read P; Population Health Strategy & Performance, NSW Health, Sydney, NSW 2065, Australia.
  • Marks P; NSW Users and AIDS Association, Surry Hills, NSW 2010, Australia.
  • Degenhardt L; Department of Health Systems and Populations, Macquarie University, Sydney, NSW 2109, Australia.
  • Hayllar J; Kirketon Road Centre, Sydney, NSW 2010, Australia.
  • Reid D; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Gorton C; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.
  • Lam T; Alcohol and Drug Service, Metro North Mental Health, Metro North Hospital and Health Service, Brisbane, QLD 4029, Australia.
  • Christmass M; Drug and Alcohol Service, Illawarra Shoalhaven Local Health District, Wollongong, NSW 2500, Australia.
  • Wade A; Cairns Sexual Health Service, Cairns, QLD 4870, Australia.
  • Montebello M; Drug Health, Western Sydney Local Health District, Sydney, NSW 2145, Australia.
  • Dore GJ; Next Step Community Alcohol and Drug Service, Perth, WA 6004, Australia.
  • Grebely J; National Drug Research Institute, Curtin University, Perth, WA 6102, Australia.
Viruses ; 14(7)2022 07 16.
Article in En | MEDLINE | ID: mdl-35891535
ABSTRACT
This study evaluated HCV treatment initiation among people who inject drugs (PWID) following an intervention of campaign days involving peer connection, point-of-care HCV RNA testing, and linkage to nursing support. ETHOS Engage is an observational cohort study of PWID attending 25 drug treatment clinics and needle and syringe programs in Australia (May 2018-September 2019). Point-of-care results were provided to the nurse, facilitating confirmatory testing and treatment. The study aimed to evaluate treatment uptake and factors associated with treatment at 24 months post-enrolment. There were 317 people with current HCV infection and eligible for treatment (median age 43, 65% male, 15% homeless, 69% receiving opioid agonist treatment, 70% injected in last month). Overall, 15% (47/317), 27% (85/317), 38% (120/317), and 49% (155/317) of people with current HCV infection had initiated treatment at 3-, 6-, 12-, and 24-months following testing, respectively. Homelessness (adjusted hazard ratio (aHR) 0.40; 95% confidence interval 0.23, 0.71) and incarceration in the past 12 months (vs. never, aHR0.46; 0.28, 0.76) were associated with decreased treatment initiation in the 24 months post-enrolment. This testing campaign intervention facilitated HCV treatment uptake among PWID. Further interventions are needed to achieve HCV elimination among people experiencing homelessness or incarceration.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Substance Abuse, Intravenous / Hepatitis C / Drug Users Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Journal: Viruses Year: 2022 Document type: Article Affiliation country: Australia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Substance Abuse, Intravenous / Hepatitis C / Drug Users Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Journal: Viruses Year: 2022 Document type: Article Affiliation country: Australia